Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04161157 · ClinicalTrials.gov registry record · NA
Piloting Pathways With Lung Cancer Patients
A NA study, sponsored by Laurie McLouth.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT04161157: Completed NA study, sponsored by Laurie McLouth.
NCT04161157 is a NA study that has completed, run by Laurie McLouth. The registered enrollment target is 53 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04161157, a NA study, has completed, sponsored by Laurie McLouth.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.
Primary Outcome
Percentage of eligible and approached patients who agree to participate
Interventions
- BEHAVIORAL Pathways
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2022-08-03 |
| Phase | NA |
What the finished NCT04161157 record still lists
NCT04161157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Pathways is the first listed.
NCT04161157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04161157 about?
NCT04161157 is a clinical study titled "Piloting Pathways With Lung Cancer Patients". The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.
What is the current status of trial NCT04161157?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2020-01-13. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT04161157?
The interventions under investigation include: Pathways (BEHAVIORAL).
Who is sponsoring clinical trial NCT04161157?
This trial is sponsored by Laurie McLouth, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04161157's enrollment target sits among peer trials
53 1271st of 2000 higher than 729 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI